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Herpes simplex virus (HSV) infection is a possible patho-
genic factor in Behçet’s disease (BD). Using proteomics 
analysis, this study detected a target HSV protein. Serum 
IgA and IgG reactivities against the identified protein 
were evaluated in patients with BD and in BD-like mice. 
A total of 4 protein bands generated by immunopreci-
pitation were analysed by proteomics, and HSV UL48 
was commonly found in both IgA- and IgG-reactive pro-
tein bands. Compared with controls, patients with BD 
and BD-like mice exhibited higher titres of IgA reacting 
with recombinant HSV UL48 protein. Further proteo-
mics analysis revealed that human heat shock cognate 
71 kDa protein (Hsc71) is a cross-reacting target antigen 
against anti-HSV UL48 antibody. In addition, our data 
demonstrated a very strong association between serum 
IgG reactivity against recombinant human Hsc71 and 
recombinant HSV UL48 in patients with BD. We suggest 
that HSV infection and impaired human Hsc71 activity 
may be associated with the activation of autoreactive 
lymphocytes. Key words: Behçet’s disease; herpes simplex 
virus; UL48; Behçet’s disease-like mouse model; proteo-
mics; heat shock cognate 71 kDa protein.
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Behçet’s disease (BD) is an autoimmune or autoinflam-
matory disorder that causes chronic multisystemic vascu-
litis (1, 2). However, the exact pathogenesis of vascular 
inflammatory reactions in BD is unknown. Although BD 
is not considered a classical infectious disease, microbial 
infection and associated immune dysregulation have been 
suggested as a major triggering factor in the pathogenesis 
of the disorder (2, 8). Among the suggested infectious 
agents, Streptococcus sanguinis and herpes simplex vi-
rus (HSV) are thought to play a crucial role in inducing 
dysregulated immune reaction in this disease (5, 8). 
Bacterial heat shock proteins (Hsp) have structural 
similarities with human Hsps and can induce strong 
immunological reactions in humans (9–12). To date, se-
veral studies have demonstrated that various infectious 
organisms can induce multiple cross-reactions with 
human proteins in genetically predisposed individu-
als, resulting in the development of organism-specific 
autoimmune diseases (9–12). Our study group also 
previously demonstrated that serum IgA antibody in 
patients with BD significantly reacts with human hete-
rogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 in 
endothelial cells and chaperonin GroEL of S. sanguinis 
(9, 13). In the current study patients with BD exhibited 
serum IgA cross-reactivity against human hnRNP A2/
B1 and S. sanguinis GroEL, and marked serum IgA 
reactivity against specific homologous epitope regions 
of these proteins (9, 13). 
Following the discovery of evidence of HSV infec-
tion in the saliva and the ulcerative lesions of patients 
with BD, the pathogenetic role of HSV in BD has been 
investigated (4, 7, 8). In addition, a BD-like mouse 
model has been developed by inoculating HSV into the 
earlobes of mice, triggering HSV-induced dysregulated 
immune responses and BD-like multi-organ symptoms 
(14, 15). 
The aim of the present study was to identify anti-HSV 
antigens that react with serum IgA and/or IgG in patients 
with BD. As described in previous studies (9, 13), target 
HSV proteins were screened using immunoprecipita-
tion, and liquid chromatography-matrix-assisted laser 
desorption/ionization-tandem time-of-flight (LC-MAL-
DI-TOF/TOF) was performed to analyse the detected 
protein bands. The serum reactivity of the recombinant 
HSV target protein in patients with BD and a HSV-
induced BD-like mouse model were then investigated, 
using enzyme-linked immunosorbent assay (ELISA) 
and Western blot analysis. 
MATERIALS AND METHODS
Patients
A total of 60 patients with BD (19 males, 41 females; mean 
age 40.9 ± 10.8 years; age range 19–63 years) were included 
in this study, in whom BD was diagnosed according to the 
diagnostic criteria set by the International Study Group for 
BD (16). The following symptoms were observed, in order of 
most to least frequent: recurrent oral ulcers (n = 60, 100%), skin 
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lesions (n = 55, 91.7%), genital ulcers (n = 50, 83.3%), articular 
involvement (n = 30, 50%), ocular involvement (n = 17, 28.3%), 
gastrointestinal lesions (n = 4, 6.7%), vascular involvement 
(n = 1, 1.7%), and epididymitis (n = 1, 1.7%). Positivity for 
HLA-B51 was noted in 17 patients (28.3%). Serum samples 
were obtained from all of the patients with BD when they 
were in a clinically active disease state, presenting at least 2 
major criteria. Samples were stored at –70°C. Purchased sera 
from 60 healthy donors (Innovative Research Inc., Novi, MI, 
USA) were included as controls. This study was approved by 
the Institutional Review Board of Severance Hospital, Yonsei 
University College of Medicine, Seoul, Korea.
Behçet’s disease-like mouse model
A BD-like mouse model was developed by inoculating HSV 
type 1 grown in Vero cells in 4–5-week-old male Institute 
of Cancer Research (ICR) mice (14). Briefly, the earlobes 
of experimental mice were scratched with a needle and they 
were inoculated twice with the virus, with a 10-day interval. 
The infected mice were observed for 16 weeks after the final 
inoculation. HSV-inoculated mice presenting at least 2 BD-like 
symptoms were used as a BD-like mouse model (n = 5) (14, 
15). Both uninfected ICR mice (n = 2) and HSV-inoculated, 
but asymptomatic, mice (n = 2) were included as controls. The 
animal study was approved by the animal care committee of the 
Ajou University School of Medicine (Suwon, Korea).
Immunoprecipitation and liquid chromatography-matrix-assisted 
laser desorption/ionization-tandem time-of-flight analysis (see 
Appendix S11)
Construction of expression vectors and bacterial expression (see 
Appendix S11)
Western blotting using recombinant herpes simplex virus type 
1 UL48 (see Appendix S11)
Enzyme-linked immunosorbent assay (see Appendix S11)
Immunohistochemical study (see Appendix S11) 
Statistical analysis
Values for quantitative variables are described as the median 
and interquartile range (IQR). Serum reactivity against re-
combinant HSV type 1 UL48 and recombinant human Hsc71 
proteins were compared between patients with BD and healthy 
subjects, as well as between BD mice and control mice, using 
non-parametric Mann-Whitney U tests, χ2 tests, Fisher’s exact 
tests, and Spearman’s rank correlation coefficients. The diag-
nostic accuracy of Western blotting and ELISA using recom-
binant HSV type 1 UL48 protein were analysed in patients 
with BD by the area under the receiver operating characteristic 
curve (AUROC) with comparisons using DeLong’s method. 
All analyses were performed using SAS software version 9.2 
(SAS Institute Inc., Cary, NC, USA). All p-values < 0.05 were 
considered statistically significant.
RESULTS
Immunoprecipitation and proteomics analysis 
Extracts of HSV reacting with IgA and IgG antibodies, 
respectively, were immunoprecipitated in serum samp-
les from 5 patients with BD (Fig. 1a, b). A total of 4 
protein bands obtained by IgA (n = 2) and IgG (n = 2) 
immunoprecipitation were analysed by LC-MALDI-
TOF/TOF, and the National Center for Biotechnology 
Information (NCBI) database was then searched for the 
DNA sequence corresponding to these 4 protein bands. 
After excluding data containing false positives and 
immunoglobulins, the viral proteins were specifically 
found to yield a Mascot score greater than 30 as shown 
in Table 1. Among the identified proteins, HSV UL48 
was commonly found in both IgA- and IgG-reactive 
protein bands with Mascot scores of 158 and 173 and 
sequence coverages of 14% and 16%, respectively. 
Therefore, we further investigated HSV UL48 (VP16) 
protein in the present study.
Fig. 1. Western blotting and immunoprecipitation using herpes simplex virus (HSV) and human dermal microvascular endothelial cells (HDMEC). 
Immunoprecipitation was performed to identify the anti-HSV (a) IgA and (b) IgG antibody-binding antigen using extracts of HSV with mixed serum 
samples from 5 patients with Behçet’s disease (BD). A total of 4 protein bands obtained by immunoprecipitation (arrows) were analysed by proteomics. 
(c) Western blotting was performed to screen the reactive HDMEC antigens against anti-HSV UL48 antibody using HSV, HSV-infected HDMEC, and 
HDMEC. (d) Immunoprecipitation was subsequently performed using HDMEC antigen and anti-HSV UL48 antibody, and 3 protein bands (arrows) 
were analysed by proteomics.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2127
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Serum reactivity against recombinant herpes simplex 
virus UL48 in patients with Behçet’s disease
ELISA and Western blot analysis with recombinant 
HSV UL48 were performed to evaluate serum reacti-
vity in sera from 30 patients with BD and 30 healthy 
controls. The median optical density (ODs) (IQR) 
of serum IgA reactivity against recombinant HSV 
UL48 obtained from ELISA were estimated as 0.35 
(0.02–1.01) in patients with BD and 0.16 (0.02–0.40) 
in healthy controls (p < 0.001) (Fig. 2a). Western blot 
analyses revealed the reactivity of serum IgA against 
recombinant HSV UL48 in 10 patients with BD 
(33.3%) and 2 healthy controls (6.7%) (p = 0.010) (Fig. 
2c). In addition, the median ODs (IQR) of serum IgG 
reactivity against recombinant HSV UL48 were 0.58 
(0.31–1.22) in patients with BD and 0.53 (0.18–0.74) 
in healthy controls (p > 0.05) (Fig. 2b). Western blot 
analyses revealed the reactivity of serum IgG against 
recombinant HSV UL48 in 18 patients with BD (60%) 
and 4 healthy controls (13.3%) (p < 0.001) (Fig. 2c).
For serum IgA reactivity against recombinant HSV 
type 1 UL48 protein, ELISA more accurately predicted 
the diagnosis of BD than Western blotting (AUROC 
ELISA vs. Western blotting, 0.852 vs. 0.633, p = 0.003). 
However, for serum IgG reactivity against recombinant 
HSV type 1 UL48 protein, there was no significant diffe-
rence between ELISA and Western blotting in predicting 
the diagnosis of BD (AUROC ELISA vs. 
Western blotting, 0.651 vs. 0.733, p > 0.05).
Serum reactivity against recombinant herpes 
simplex virus UL48 in a Behçet’s disease-like 
mouse model
ELISA and Western blot analysis with 
recombinant HSV UL48 were performed 
to evaluate serum reactivity in sera from 
5 BD-like mice, 2 uninfected ICR mice, 
and 2 HSV-inoculated, but asymptomatic, 
mice. The median ODs (IQR) of serum IgA 
reactivity against recombinant HSV UL48 
obtained from ELISA were estimated as 0.31 
(0.14–0.75) in BD-like mice and 0.10 (0.07–
0.14) in uninfected ICR mice and HSV-inoculated, but 
asymptomatic, mice (p = 0.037) (Fig. 3a). However, 
Western blot analyses revealed the reactivity of serum 
IgA against recombinant HSV UL48 in all 5 BD-like 
mice (100%), but not in the uninfected ICR mice or 
asymptomatic mice (p = 0.008) (data not shown).
In addition, the mean ODs of serum IgG reactivity 
against recombinant HSV UL48 obtained from ELISA 
were 0.07 (0.04–0.11) in BD-like mice and 0.04 (0.02–
0.08) in uninfected ICR mice and HSV-inoculated, 
but asymptomatic, mice (p > 0.05) (Fig. 3b). Western 
blot analyses revealed serum IgG reactivity against 
recombinant HSV UL48 in only 2 of the 5 BD-like 
mice (40%), and in none of the uninfected ICR mice 
and HSV-inoculated, but asymptomatic, mice (p > 0.05) 
(data not shown).
Immunohistochemical staining 
Tissue samples of knee joints obtained from uninfected 
ICR mice and HSV-infected, but asymptomatic, mice 
were found to have no or scanty inflammatory cell 
infiltration (Fig. 4a–d), whereas marked inflammatory 
cell infiltration was observed in the joints from BD-like 
mice (Fig. 4e, f). The experimental mice of all groups 
exhibited mild immunoreactivity to anti-HSV UL48 
antibody in the epithelium of synovial membranes. In 
Table I. Herpes simplex virus proteins that reacted with serum immunoglobulin 









  UL48 ABI63509 gi│114318835 54698/4.92 158
  Alpha trans inducing factor AAA45766 gi│330055 53396/4.95 133
  Genome polyprotein P07564 gi│130428 382498/8.75 69
IgG
  Glycoprotein D ABM52980 gi│121277019 43744/8.10 182
  UL48 ABI63509 gi│114318835 54698/4.92 173
  Alpha trans inducing factor AAA45766 gi│330055 53396/4.95 158
  Envelope glycoprotein D P06476 gi│138233 43767/8.89 107
  Glycoprotein C-1 CAD13356 gi│17426768 55560/7.16 54
  Genome polyprotein P14335 gi│130494 384959/8.70 54
Fig. 2. Enzyme-linked immunosorbent assay (ELISA) and Western blotting using recombinant herpes simplex virus (HSV) UL48 protein. (a, b) ELISA 
and (c) Western blotting using recombinant HSV UL48 was performed using the sera from patients with Behçet’s disease (BD) and healthy controls (HC) 
as a primary antibody and goat anti-human IgA and IgG antibody as a second antibody. **p < 0.01. □: negative; ■: positive.
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addition, both mononuclear cells and endothelial cells 
exhibited marked immunoreactivity to anti-HSV UL48 
antibody in joint tissue samples from BD-like mice. 
Immunoreactivity of anti-herpes simplex virus UL48 
antibody against human dermal microvascular 
endothelial cells
In order to identify an additional target protein, which 
exhibited immunoreactivity to anti-HSV UL48 antibo-
dy, Western blot analysis using HSV type 1, HDMECs 
incubated with HSV, and HDMECs was performed, 
and showed that anti-HSV UL48 polyclonal antibody 
recognized distinct protein bands in HDMECs, com-
pared with HSV type 1 (Fig. 1c). Immunoprecipitation 
was performed and 3 protein bands were analysed by 
proteomics as described above (Fig. 1d). After exclu-
ding data containing false positives and immunoglo-
bulins, 8 human proteins were specifically found to 
yield a Mascot score larger than 30 (Table II). Among 
the identified proteins, Hsc71 isoform 1 was further 
investigated in this study. 
Serum samples from another 30 patients 
with BD and 30 healthy controls were also 
obtained, and ELISAs with recombinant HSV 
UL48 protein and recombinant human Hsc71 
were performed. The median ODs (IQR) of se-
rum IgA reactivity against recombinant human 
Hsc71 were 0.35 (0.22–0.53) in patients with 
BD and 0.27 (0.18–0.35) in healthy controls 
(p > 0.05) (Fig. 5a), whereas those of serum 
IgG reactivity against recombinant human 
Hsc71 were 1.19 (0.84–1.47) in patients with 
BD and 0.90 (0.65–1.09) in healthy controls 
(p = 0.015) (Fig. 5b). In addition, the median 
ODs (IQR) of serum IgA reactivity against 
recombinant HSV UL48 were 0.67 (0.52–1.11) 
in patients with BD and 0.31 (0.12–1.02) in 
healthy controls (p < 0.0001) (Fig. 5c), whereas 
those of serum IgG reactivity against recom-
binant HSV UL48 were 0.68 (0.27–0.95) in 
patients with BD and 0.65 (0.35–0.81) in 
healthy controls (p > 0.05) (Fig. 5d).
ODs obtained from ELISAs against recom-
binant human Hsc71 were correlated with 
those against recombinant HSV UL48 in 
patients with BD: Hsc71 IgA and UL48 IgG 
(r = 0.402, p = 0.027), Hsc71 IgG and UL48 
IgA (r = –0.787, p < 0.0001), and Hsc71 IgG 
and UL48 IgG (r = 0.887, p < 0.0001) (Fig. 6). 
In ELISAs of the serum samples of healthy sub-
jects, only Hsc71 IgA and UL48 IgA (r = 0.713, 
p < 0.0001) were correlated (Fig. 6).
Fig. 3. Enzyme-linked immunosorbent 
assay (ELISA) using recombinant herpes 
simplex virus (HSV) UL48 protein in 
a Behçet’s disease (BD)-like mouse 
model. ELISA using recombinant HSV 
UL48 was performed using the sera 
from BD-like mice, uninfected Institute 
of Cancer Research (ICR) mice (HC), 
and HSV-inoculated, but asymptomatic, 
mice (Asx) as a primary antibody and 
goat anti-mouse (a) Immunoglobulin 
(Ig)A and (b) IgG antibody as a second 
antibody. *p < 0.05.
Fig. 4. Immunochemical staining of herpes simplex virus (HSV) UL48. Tissue samples 
of knee joints obtained from (a, b) uninfected ICR mouse, (c, d) asymptomatic mouse, 
and (e, f) Behçet’s disease (BD)-like mice were stained with anti-HSV UL48 antibody. 
Mononuclear cells and endothelial cells presented marked immunoreactivity to anti-
HSV UL48 antibody in tissue samples from BD-like mice. Bars = 100 μm.
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DISCUSSION
HSV is composed of 4 components, including a double-
stranded DNA-containing electron-dense core, an 
icosadeltahedral capsid, a tegument, and an envelope 
(17). Tegument proteins have been shown to stimulate 
transcription of viral genes and counteract host defen-
ces to survive within an infected host (18). UL48, an 
abundant 65-kDa virion phosphoprotein, is one of the 
surrounding tegument proteins. This protein is synthe-
sized late in infection and has a potent transcriptional 
activation domain on its C-terminal portion (18, 19). 
UL48 also modulates host innate anti-viral immune 
responses by antagonizing interferon (IFN)-β produc-
tion by inhibiting NF-κB and blocking IFN regulatory 
factor (IRF)-3 (18). 
In the present study, we demonstrated HSV UL48 
protein as a target protein of serum anti-HSV IgA and 
IgG antibodies in patients with BD and a 
BD-like mouse model. Thirty patients with 
BD exhibited higher titres of IgA and IgG 
reacting with recombinant HSV UL48, com-
pared with controls, by ELISA; nevertheless, 
statistical significance was observed only for 
anti-HSV UL48 IgA antibody. When we ad-
ditionally collected the serum samples from 
another 30 patients with BD and 30 healthy 
controls for ELISAs, the results of serum 
IgA and IgG reactivity against recombinant 
HSV UL48 were compatible with those of 
the aforementioned 30 patients with BD and 
30 healthy controls. 
Our data also revealed marked immunostaining of 
anti-HSV UL48 antibody in tissue samples obtained 
from the knee joints of BD-like mice, compared with 
those from the control experimental mice. Thereafter, 
we further investigated cross-reacting target antigens 
with anti-HSV UL48 antibody, and proteomics analyses 
revealed that human Hsc71 also reacted with anti-HSV 
UL48 antibody. ODs obtained from ELISA demonstra-
ted a very strong association (r > 0.8) between serum 
IgG reactivity against recombinant human Hsc71 and 
recombinant HSV UL48 in patients with BD. In addi-
tion, strong association (0.8 > r ≥ 0.6) was found bet-
ween serum IgG reactivity against recombinant human 
Hsc71 and serum IgA reactivity against recombinant 
HSV UL48 in patients with BD.
Hsc71 is a constitutively expressed form of Hsp70 
and transports cytosolic proteins to lysosomes for 
proteasomal degradation (20, 21). The precise role of 
Hsp70 family and anti-Hsp70 family anti-
bodies in the pathogenesis of autoimmune 
disease remains unknown (21, 22). Potent 
immunomodulatory properties of human 
Hsp70 have been reported to regulate T-cell 
activities, and microbial Hsp70 has also been 
shown to suppress host inflammatory reactions 
(22–24). A recent investigation suggested that 
Hsp70 may maintain immune homeostasis by 
enhancing the immunosuppressive activity 
of Tregs to neutralize exaggerated immune 
responses (22). 
As Hsps are highly conserved proteins, 
which are widely expressed in both proka-
ryotes and eukaryotes with high degree of 
homology, common immunogenic epitopes 
have been found between Hsp70 family and 
autoantigens, as well as infectious organisms 
(25). Previous in vivo study demonstrated that 
the administration of both Hsp70 and antigen 
can induce autoimmunity (26). Anti-Hsp70 
family antibodies have been detected in the 
sera of patients with various autoimmune 
disorders, including systemic lupus erythe-
Table II. Proteins of human dermal microvascular endothelial cells that reacted 





accession No. Mr (kDa)/pI
Mascot 
score
Keratin 1 AFA52006 gi│375314779 66197/8.15 681
Epidermal cytokeratin 2 AAC83410 gi│181402 66110/8.07 324
Vimentin CAG28618 gi│47115317 53604/5.09 214
Keratin 6B isoform CRA_a EAW96626 gi│119617032 60159/8.38 158
HSC71 kDa protein isoform 1 NP_006588 gi│5729877 71082/5.37 79
Alpha-tubulin CAA25855 gi│37492 50810/5.02 73
Factor VII active site mutant ic AAK58686 gi│28269794 77386/6.60 65
MTHSP75 AAA67526 gi│292059 74019/5.97 62
NCBI: National Center for Biotechnology Information; HSC: heat shock cognate; ic: 
immunoconjugate.
Fig. 5. Enzyme-linked immunosorbent assays (ELISAs) using recombinant human heat 
shock cognate 71 kDa (Hsc71) protein and recombinant herpes simplex virus (HSV) 
UL48 protein. ELISAs were performed using the sera from patients with Behçet’s 
disease (BD) and healthy controls (HC) as a primary antibody and goat anti-human 
IgA and IgG antibody as a second antibody against (a, b) recombinant human Hsc71 
HSV UL48 and (c, d) recombinant HSV UL48. *p < 0.05; **p < 0.01. Median (blue 
line) and interquartile range (red line).
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matosus, rheumatoid arthritis, mixed connective tissue 
disease, idiopathic thrombocytopenic purpura, and my-
asthenia gravis (20, 27). Paediatric patients with immune 
thrombocytopenic purpura, which is an autoimmune 
platelet-destructive disease, reportedly exhibit a high 
prevalence of IgG autoantibody against Hsp71 in plasma 
(27). As well, significantly higher titres of anti-Hsc71 
antibody were detected in patients with myasthenia gra-
vis, compared with the healthy controls (20). In addition, 
“therapy-responsive group” patients with myasthenia 
gravis exhibited significantly reduced Hsc71 antibody 
titres, in addition to clinical improvement (20).
In the previous report, patients with BD also exhibited 
significantly elevated human Hsp70 and anti-Hsp70 
antibodies, and the authors suggested the crucial role of 
Hsp70-mediated innate and adaptive immune responses 
in the pathogenesis of BD by activating proinflam-
matory cytokine (28). In addition, the serum levels of 
Hsp70 were elevated in patients with BD with uveitis 
compared with either patients with BD without uveitis 
or idiopathic uveitis (29). However, there was no sta-
tistical difference among BD with uveitis, BD without 
uveitis, and idiopathic uveitis in the serum anti-Hsp70 
antibody levels (29). Overexpressed Hsc71 inhibits 
host cellular antiviral responses by suppressing virus-
triggered transcription of IFNB1 gene and IFN-β ex-
pression, as also observed for HSV UL48 protein (30). 
In the present study, significantly higher levels of se-
rum IgA reactivity against recombinant HSV UL48 on 
ELISA were found in patients with BD, compared with 
healthy controls. In addition, patients with BD exhibited 
remarkable serum IgG reactivity against recombinant 
Hsc71, which was strongly associated with serum IgG 
reactivity against recombinant HSV UL48. In an effort 
to control antibody reactivity in various autoimmune di-
seases, several anti-viral treatments have been investiga-
ted (31). One such study demonstrated that oral acyclovir 
treatment could not effectively reduce the frequency and 
severity of BD-associated mucosal and ocular symptoms 
(32). Meanwhile, oral famciclovir treatment was shown 
to be effective in a BD-like mouse model (33). Since 
serum anti-HSV IgA and IgG antibodies present peaks 
with primary HSV infection and also show high levels 
during recurrent episodes, administering anti-viral agents 
with or without combined immune modulating treatments 
to reduce serum levels of anti-HSV antibodies may be a 
potential therapeutic option in BD (32–35).
Although we cannot describe the precise pathogenetic 
role of HSV UL48 or human Hsc71 in patients with 
BD, we suggest that HSV infection, especially massive 
exposure to the HSV UL48 protein, and impairment of 
human Hsc71 activity may be associated with the acti-
vation of autoreactive lymphocytes. However, further 
investigations are necessary to elucidate the roles of 
HSV UL48 and human Hsc71, as well as circulating 
IgA and IgG autoantibodies, against these proteins in 
patients with BD.
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